AlgiPharma Phase I clinical trial shows excellent safety and tolerability data for respiratory diseases

OligoG CF-5/20 was well tolerated when administered by inhalation to 28 healthy subjects. All adverse events monitored were mild and transient. No serious adverse events, no deaths, no discontinuations. Read more ClinicalTrials.gov For more information contact: Yngvar P. Berg, CEO; [email protected] Astrid Hilde Myrset, Clinical Director; [email protected] January 2010

The release as fetched from its publisher. algipharma.com ↗